176 related articles for article (PubMed ID: 35103233)
1. Loss of EphA7 Expression in Basal Cell Carcinoma by Hypermethylation of CpG Islands in the Promoter Region.
Liu J; Yu N; Feng X; He Y; Lv K; Zhu H; Wang J
Anal Cell Pathol (Amst); 2022; 2022():4220786. PubMed ID: 35103233
[TBL] [Abstract][Full Text] [Related]
2. Loss of ARHGAP40 expression in basal cell carcinoma via CpG island hypermethylation.
Yu N; Yuan B; Cai J; Liu J; Zhang W; Bao W; Wang J
Exp Dermatol; 2023 Dec; 32(12):2094-2101. PubMed ID: 37822129
[TBL] [Abstract][Full Text] [Related]
3. Downregulation of EphA7 by hypermethylation in colorectal cancer.
Wang J; Kataoka H; Suzuki M; Sato N; Nakamura R; Tao H; Maruyama K; Isogaki J; Kanaoka S; Ihara M; Tanaka M; Kanamori M; Nakamura T; Shinmura K; Sugimura H
Oncogene; 2005 Aug; 24(36):5637-47. PubMed ID: 16007213
[TBL] [Abstract][Full Text] [Related]
4. Aberrant methylation of EphA7 in human prostate cancer and its relation to clinicopathologic features.
Guan M; Xu C; Zhang F; Ye C
Int J Cancer; 2009 Jan; 124(1):88-94. PubMed ID: 18821581
[TBL] [Abstract][Full Text] [Related]
5. Differential expression of EphA7 receptor tyrosine kinase in gastric carcinoma.
Wang J; Li G; Ma H; Bao Y; Wang X; Zhou H; Sheng Z; Sugimura H; Jin J; Zhou X
Hum Pathol; 2007 Nov; 38(11):1649-56. PubMed ID: 17669470
[TBL] [Abstract][Full Text] [Related]
6. Secreted form of EphA7 in lung cancer.
Tsuboi M; Mori H; Bunai T; Kageyama S; Suzuki M; Okudela K; Takamochi K; Ogawa H; Niwa H; Shinmura K; Sugimura H
Int J Oncol; 2010 Mar; 36(3):635-40. PubMed ID: 20126984
[TBL] [Abstract][Full Text] [Related]
7. Aberrant methylation and silencing of ARHI, an imprinted tumor suppressor gene in which the function is lost in breast cancers.
Yuan J; Luo RZ; Fujii S; Wang L; Hu W; Andreeff M; Pan Y; Kadota M; Oshimura M; Sahin AA; Issa JP; Bast RC; Yu Y
Cancer Res; 2003 Jul; 63(14):4174-80. PubMed ID: 12874023
[TBL] [Abstract][Full Text] [Related]
8. Epigenetic changes in Basal Cell Carcinoma affect SHH and WNT signaling components.
Brinkhuizen T; van den Hurk K; Winnepenninckx VJ; de Hoon JP; van Marion AM; Veeck J; van Engeland M; van Steensel MA
PLoS One; 2012; 7(12):e51710. PubMed ID: 23284750
[TBL] [Abstract][Full Text] [Related]
9. The identification and validation of EphA7 hypermethylation, a novel biomarker, in cervical cancer.
Zhang W; Cao H; Yang J; Zhao J; Liang Z; Kang X; Wang R
BMC Cancer; 2022 Jun; 22(1):636. PubMed ID: 35681118
[TBL] [Abstract][Full Text] [Related]
10. Association between SNPs and Loss of Methylation Site on the CpG island of the Promoter Region of the Smoothened Gene, Potential Molecular Markers for Susceptibility to the Development of Basal Cell Carcinoma in the Brazilian Population.
Souza AM; Lopes OS; Liberato AL; Oliveira PJR; Herrero SST; Nascimento ALD; Longui CA; Carvalho Filho IR; Soares LF; Silva RBD; Burbano RR; Delatorre P; Lima EM
Asian Pac J Cancer Prev; 2020 Jan; 21(1):25-29. PubMed ID: 31983159
[TBL] [Abstract][Full Text] [Related]
11. Methylation status, mRNA and protein expression of the SMAD4 gene in patients with non-melanocytic skin cancers.
Gürsel Ürün Y; Budak M; Usturalı Keskin E
Mol Biol Rep; 2023 Sep; 50(9):7295-7304. PubMed ID: 37428273
[TBL] [Abstract][Full Text] [Related]
12. Analysis of 14-3-3sigma expression in hyperproliferative skin diseases reveals selective loss associated with CpG-methylation in basal cell carcinoma.
Lodygin D; Yazdi AS; Sander CA; Herzinger T; Hermeking H
Oncogene; 2003 Aug; 22(35):5519-24. PubMed ID: 12934112
[TBL] [Abstract][Full Text] [Related]
13. Basal cell carcinoma and its development: insights from radiation-induced tumors in Ptch1-deficient mice.
Mancuso M; Pazzaglia S; Tanori M; Hahn H; Merola P; Rebessi S; Atkinson MJ; Di Majo V; Covelli V; Saran A
Cancer Res; 2004 Feb; 64(3):934-41. PubMed ID: 14871823
[TBL] [Abstract][Full Text] [Related]
14. Expression of p16 Protein in Cutaneous Basal Cell Carcinoma: Still far from Being Clearly Understood.
Bartoš V
Acta Dermatovenerol Croat; 2020 Jul; 28(1):43-44. PubMed ID: 32650852
[TBL] [Abstract][Full Text] [Related]
15. Epigenetic silencing contributes to frequent loss of the fragile histidine triad tumour suppressor in basal cell carcinomas.
Goldberg M; Rummelt C; Laerm A; Helmbold P; Holbach LM; Ballhausen WG
Br J Dermatol; 2006 Dec; 155(6):1154-8. PubMed ID: 17107382
[TBL] [Abstract][Full Text] [Related]
16. miR‑18a‑5p promotes melanoma cell proliferation and inhibits apoptosis and autophagy by targeting EPHA7 signaling.
Guo Y; Shi W; Fang R
Mol Med Rep; 2021 Jan; 23(1):. PubMed ID: 33236144
[TBL] [Abstract][Full Text] [Related]
17. Global DNA methylation profiling reveals silencing of a secreted form of Epha7 in mouse and human germinal center B-cell lymphomas.
Dawson DW; Hong JS; Shen RR; French SW; Troke JJ; Wu YZ; Chen SS; Gui D; Regelson M; Marahrens Y; Morse HC; Said J; Plass C; Teitell MA
Oncogene; 2007 Jun; 26(29):4243-52. PubMed ID: 17260020
[TBL] [Abstract][Full Text] [Related]
18. Epigenetic alterations in sporadic basal cell carcinomas.
Stamatelli A; Vlachou C; Aroni K; Papassideri I; Patsouris E; Saetta AA
Arch Dermatol Res; 2014 Aug; 306(6):561-9. PubMed ID: 24573469
[TBL] [Abstract][Full Text] [Related]
19. Increased expression of EphA7 correlates with adverse outcome in primary and recurrent glioblastoma multiforme patients.
Wang LF; Fokas E; Juricko J; You A; Rose F; Pagenstecher A; Engenhart-Cabillic R; An HX
BMC Cancer; 2008 Mar; 8():79. PubMed ID: 18366728
[TBL] [Abstract][Full Text] [Related]
20. PTCH promoter methylation at low level in sporadic basal cell carcinoma analysed by three different approaches.
Heitzer E; Bambach I; Dandachi N; Horn M; Wolf P
Exp Dermatol; 2010 Oct; 19(10):926-8. PubMed ID: 20849535
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
